AgomAb Therapeutics NV (AGMB)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Tim Knotnerus MSc, Ph.D.
|
CEO & Executive Director | -- | -- | 1983 |
|
Mr. Paolo Michieli Ph.D.
|
Founder, Senior Advisor & Member of Scientific Advisory Board | -- | -- | -- |
|
Mr. Pierre Kemula B.Sc.
|
Chief Financial Officer | -- | -- | 1974 |
|
Sofie Van Gijsel
|
Vice President of Investor Relations | -- | -- | -- |
|
Ms. Ellen Lefever
|
General Counsel | -- | -- | 1985 |
|
Dr. Philippe Wiesel M.D.
|
Chief Medical Officer | -- | -- | 1967 |
|
Dr. Paul Van Der Horst Ph.D.
|
Chief Business Officer | -- | -- | 1988 |
|
Dr. Andrea Sáez Borderías Ph.D.
|
Chief Development Officer | -- | -- | 1982 |
AgomAb Therapeutics NV
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 62
Description
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
